Alarmin IL-33 |
|
Vaxjo ID |
212 |
|
Vaccine Adjuvant Name |
Alarmin IL-33 |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
IL-33 is an "Alarmin" with pleiotropic properties. It acts as an immunoadjuvant to enhance antigen-specific tumor immunity. It influences CD4 T helper 1 or CD8 T-cell immune responses, enhancing potent antigen-specific effector and memory T-cell immunity. It drives robust IFN-¦Ã responses and augments vaccine-induced antigen-specific polyfunctional CD4(+) and CD8(+) T-cell responses. |
|
Stage of Development |
Research |
|
Components |
Studies of interleukin (IL)-33 reveal a number of pleiotropic properties |
|
Structure |
Two biologically active isoforms exist: full-length and mature. |
|
Dosage |
none |
|
Function |
Two biologically active isoforms of IL-33 exist that are full-length or mature, but the ability of either isoform to function as a vaccine adjuvant that influences CD4 T helper 1 or CD8 T-cell immune responses is not defined. |
|
Safety |
The study indicated that neither IL-4 nor immunoglobulin E levels were elevated, suggesting no elevation of allergic response indicators. |
| Related Vaccine(s) |
|
| References |
Villarreal et al., 2014: Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer research. 2014; 74(6); 1789-1800. [PubMed: 24448242].
|
